The Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) on Tuesday issued warnings to consumers about the potential risks of the cannabinoid delta-8 THC, a psychoactive compound that has grown in popularity but exists in an especially grey regulatory space.
While lawmakers have specified that hemp is only federally legal if it contains no more than 0.3 percent delta-9 THC, the most commonly known and naturally occurring cannabinoid, there’s generally a lack of rules governing delta-8 THC, which can be synthesized using CBD from legal hemp.
FDA and CDC have taken notice of the growing availability and demand for delta-8 THC, which is being sold in states regardless of whether they’ve legalized marijuana. And the agencies say they’re seeing a significant uptick in reported adverse health effects from people who are using it.
“It is important for consumers to be aware that delta-8 THC products have not been evaluated or approved by the FDA for safe use in any context,” FDA said. “They may be marketed in ways that put the public health at risk and should especially be kept out of reach of children and pets.”
The agency said some delta-8 products are being labeled as “hemp,” which could mislead consumers who are seeking non-intoxicating cannabinoids from the plant. And from December 2020 to July 2021, FDA said it has logged 22 adverse events reports from people who’ve experience symptoms such as “vomiting, hallucinations, trouble standing, and loss of consciousness.”
Published: September 14, 2021
Founder & Interim Editor of L.A. Cannabis News